ArticleStem cells international2011
Phenotypic definition of the progenitor cells with erythroid differentiation potential present in human adult blood.
Article in Stem cells international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Knock Out of miRNA-30a-5p and Reconstitution of the Actin Network Dynamics Partly Restores the Impaired Terminal Erythroid Differentiation during Blood Pharming.Stem cell reviews and reports · 2025Article
- Review
- Continuous Change in Membrane and Membrane-Skeleton Organization During Development From Proerythroblast to Senescent Red Blood Cell.Frontiers in physiology · 2018Review
- Polyurethane scaffolds seeded with CD34(+) cells maintain early stem cells whilst also facilitating prolonged egress of haematopoietic progenitors.Scientific reports · 2016Article
- Mathematical modeling reveals differential effects of erythropoietin on proliferation and lineage commitment of human hematopoietic progenitors in early erythroid culture.Haematologica · 2016Article
- Article
- The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis.American journal of blood research · 2014Article
- Manufacturing blood ex vivo: a futuristic approach to deal with the supply and safety concerns.Frontiers in cell and developmental biology · 2014Review
- HIV-1 Nef impairs key functional activities in human macrophages through CD36 downregulation.PloS one · 2014Article
- Ex-vivo expansion of red blood cells: how real for transfusion in humans?Blood reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Human Erythroid Massive Amplification (HEMA) cultures, AB mononuclear cells (MNC) generate 1-log more erythroid cells (EBs) than the corresponding CD34(pos) cells, suggesting that MNC may also contain CD34(neg) HPC. To clarify the phenotype of AB HPC which generate EBs in these cultures, flow cytometric profiling for CD34/CD36 expression, followed by isolation and functional characterization (colony-forming-ability in semisolid-media and fold-increase in HEMA) were performed. Four populations with erythroid differentiation potential were identified: CD34(pos)CD36(neg) (0.1%); CD34(pos)CD36(pos) (barely detectable-0.1%); CD34(neg)CD36(low) (2%) and CD34(neg)CD36(neg) (75%). In semisolid-media, CD34(pos)CD36(neg) cells generated BFU-E and CFU-GM (in a 1 : 1 ratio), CD34(neg)CD36(neg) cells mostly BFU-E (87%) and CD34(pos)CD36(pos) and CD34(neg)CD36(low) cells were not tested due to low numbers. Under HEMA conditions, CD34(pos)CD36(neg), CD34(pos)CD36(pos), CD34(neg)CD36(low) and CD34(neg)CD36(neg) cells generated EBs with fold-increases of ≈9,000, 100, 60 and 1, respectively, and maturation times (day with >10% CD36(high)CD235a(high) cells) of 10-7 days. Pyrenocytes were generated only by CD34(neg)/CD36(neg) cells by day 15. These results confirm that the majority of HPC in AB express CD34 but identify additional CD34(neg) populations with erythroid differentiation potential which, based on differences in fold-increase and maturation times, may represent a hierarchy of HPC present in AB.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.